Prevention of recurrent uric acid and calcium oxalate stones by administration of the xanthine oxidase inhibitors Milurit 100 and Milurit 300.
Disturbances in purine metabolism with hyperuricaemia and/or hyperuricosuria are a risk factor in uric acid and Ca oxalate stone formation. By way of a competitive xanthine oxidase inhibition, the formation of uric acid is reduced by allopurinol. In investigations on two groups of patients, Milurit could be demonstrated to decrease the uric acid levels in serum and urine. No differences could be seen in the dosages of 3 x 100 mg or 1 x 300 mg Milurit. Therefore, in stone recurrence prevention, the administration of Milurit 300 is recommended.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000008:administration & dosage* / Q000494:pharmacology; D002129:Calcium Oxalate / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010117:Oxypurinol / Q000097:blood / Q000652:urine; D012008:Recurrence; D014527:Uric Acid / Q000097:blood / Q000652:urine*; D014545:Urinary Calculi / Q000188:drug therapy* / Q000652:urine; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D002129:Calcium Oxalate; D014527:Uric Acid; D000493:Allopurinol; D014969:Xanthine Oxidase; D010117:Oxypurinol